Cholesterol

PreclinicalSmall molecule

EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Cholesterol is one of 4 small molecule programs targeting Smith-Lemli-Opitz syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Smith-Lemli-Opitz SyndromeActive, not recruiting

Smith-Lemli-Opitz SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Smith-Lemli-Opitz Syndrome

#DrugCompanyPhaseTrials

Zocor

OOrganon and Co

Approved

—2

Antioxidants

IInstitute of Child Health

Phase 2

1 3

Cholbam

MMirum Pharmaceuticals, Inc.

Phase 2

1 4

Cholesterol

EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Smith-Lemli-Opitz syndrome2 trials

Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT01773278·100 enrolled

Clinical and Basic Investigations Into Smith-Lemli-Opitz Syndrome

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)··NCT00001721·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cholesterol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cholesterol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cholesterol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Cholesterol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Smith-Lemli-Opitz syndrome2 trials

References

Drug Info

Quick Facts

Related News